Yu Jiajun, Zuo Tian, Peng Sihan, Xu Danping
Traditional Chinese Medicine Department, The Eighth Affiliated Hospital, Sun Yat-sen University (FuTian, Shenzhen), Shenzhen, Guangdong, China.
Intensive Care Unit, Fangcun Branch Hospital, Guangdong Provincial Hospital of Chinese Medicine, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China.
Front Cardiovasc Med. 2025 Aug 25;12:1499449. doi: 10.3389/fcvm.2025.1499449. eCollection 2025.
Increasing evidence has indicated the potential correlation between Systemic Immune-Inflammation Index (SII) and the incidence and prognosis of patients with heart failure (HF). However, the association remains unraveled in the existing research.
A literature search was systematically conducted across PubMed, Embase, Web of Science, and the Cochrane Library from their respective inceptions to July 2024, aiming to identify studies investigating the association between SII and both the incidence and clinical outcomes of HF patients. The primary outcomes included incidence and mortality rates, which were assessed using risk ratios (RR) and corresponding 95% confidence intervals (CIs). To assess the robustness of the findings and to identify potential sources of heterogeneity, sensitivity analyses and subgroup analyses were conducted. Meta-analyses were carried out using Review Manager (v5.4) and STATA (v15.0).
Fifteen studies comprising 77,917 patients were included. The pooled data demonstrated no significant association between SII and the incidence of HF (RR = 1.22, 95%CI: 0.92-1.62; = 0.16). However, a significant correlation was identified between elevated SII and increased mortality risk (RR = 1.44, 95%CI: 1.29-1.61; < 0.00001). Furthermore, subgroup analyses revealed the association between SII and mortality in patients with HF was not influenced by sample size, age, country, study design, or ejection fraction. In contrast, the association between SII and incidence of HF was affected by country, while no significant effect was observed in the other subgroups.
As a reliable biomarker, SII exhibits significant efficacy in prognostic evaluation for HF patients and provides valuable insights to inform clinical decision-making in the HF population.
https://www.crd.york.ac.uk/PROSPERO/myprospero, PROSPERO CRD42024582003.
越来越多的证据表明全身免疫炎症指数（SII）与心力衰竭（HF）患者的发病率和预后之间存在潜在关联。然而，现有研究中这种关联仍未明确。
从PubMed、Embase、Web of Science和Cochrane图书馆各自建库起至2024年7月进行了系统的文献检索，旨在识别研究SII与HF患者发病率及临床结局之间关联的研究。主要结局包括发病率和死亡率，使用风险比（RR）及相应的95%置信区间（CI）进行评估。为评估研究结果的稳健性并识别潜在的异质性来源，进行了敏感性分析和亚组分析。使用Review Manager（v5.4）和STATA（v15.0）进行荟萃分析。
纳入了15项研究，共77917例患者。汇总数据显示SII与HF发病率之间无显著关联（RR = 1.22，95%CI：0.92 - 1.62；P = 0.16）。然而，发现SII升高与死亡风险增加之间存在显著相关性（RR = 1.44，95%CI：1.29 - 1.61；P < 0.00001）。此外，亚组分析显示SII与HF患者死亡率之间的关联不受样本量、年龄、国家、研究设计或射血分数的影响。相比之下，SII与HF发病率之间的关联受国家影响，而在其他亚组中未观察到显著影响。
作为一种可靠的生物标志物，SII在HF患者的预后评估中显示出显著疗效，并为HF人群的临床决策提供了有价值的见解。
https://www.crd.york.ac.uk/PROSPERO/myprospero，PROSPERO CRD42024582003 。
